Clinical Trial Update: Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the combination of Rituximab with Yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with Non-Hodgkin lymphoma and the study was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (Rituxan) (rituximab)
• Zevalin (ibritumomab tiuxetan) (ibritumomab tiuxetan)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-11-21